Respiratory function can be preserved and/or enhanced in patients with a respiratory insufficiency using a photoceutical applied by a photoceutical medical device to at least one primary inspiratory muscle and/or a lung. At least one site on a body of a patient can be selected for delivery of the photoceutical to the muscle(s); and the photoceutical can be applied at the at least one site by the photoceutical medical device for a time period from a first start time to a first end time to treat the at least one primary inspiratory muscle and/or the lung of the patient to preserve and/or enhance the respiratory function. The photoceutical can include a light signal with at least one delivery scheme (e.g., superpulsed, pulsed. and/or continuous) and one or more wavelengths.

A wearable photobiomodulation device comprises a shell portion and an illumination module and is configured to deliver light to a photoresponsive tissue of an individual. In some embodiments, the illumination module provides red and/or infrared light to a photoresponsive tissue on an individual at a dose of between about 5-50 mJ/cm.sup.2 over a target illumination area of about 100-200 cm.sup.2. Exemplary devices may be configured as a wearable sports cup with an integral or detachable illumination module that provides effective amounts of light to a target are to so effect photobiomodulation in an individual wearing the device.

An implant system for photodynamic therapy with a light source for radiating light which is implantable in a resection cavity, and with an autonomous control unit which is connectable via a supply line to the light source.

The present disclosure relates to a vaginal treatment device using LEDs, high-frequency waves, and EMS, the vaginal treatment device including: a main body part configured to be inserted into a vagina and having one or more LED irradiation units configured to irradiate an interior of the vagina with light, and electrode units configured to transfer radio frequency (RF) energy or electro muscular stimulation (EMS) energy into the vagina; a handle part embedded with a battery and having a power source member connected to one end of the main body part and configured to control transmission and reception to/from the LED irradiation units or the electrode units; and a housing part electrically connected to the handle part and configured to charge the battery.

Disclosed is a lighting device for bright therapy and dark therapy, comprising: a light source part including a red light source, a green light source and a blue light source; a power supply part supplying a power to the light source part; and a controller adjusting, by controlling the power supply part, a bio illuminance to allow melatonin suppression value to exceed a first reference value during morning hours and to allow the melatonin suppression value to be less than a second reference value while maintaining a visual illuminance over a predetermined value during evening hours.

Light stimulation systems and methods for elevating testosterone levels in male patients.

A method comprises determining (203) whether a person has been and/or will be irradiated with an amount of UV radiation exceeding a threshold and controlling (205), in dependence on the determination, one or more light sources to render light comprising a light component having wavelengths in the range 550 to 900 nm. A spectral power distribution of the light is chosen such that the light has a cytochrome C oxidase efficacy complying with the following conditions: for DNA synthesis: the cytochrome C oxidase efficacy is at least 6.2*vʹ-2.48 mW/lm if the light’s vʹ is lower than 0.539 or at least 0.85 mW/lm if the light’s vʹ is equal to or higher than 0.539; for RNA synthesis: the cytochrome C oxidase efficacy is at least 7.5*vʹ-2.975 mW/lm if the light’s vʹ is lower than 0.539 or at least 1.05 mW/lm if the light’s vʹ is equal to or higher than 0.539.

Provided is a swallowable capsule for providing phototherapy to a patient's gastrointestinal (GI) tract, the capsule including a power supply, one or more phototherapeutic light sources, a speed determination unit for calculating speed of movement of the capsule in the GI tract, and a controller unit for activating one or more of the one or more light sources for delivering a therapeutic illumination dose to a target site in the GI tract, based, at least in part, on a determined speed. Related apparatus and methods are also described.

The present disclosure is directed to systems and methods that can apply low level light (LLL) to facilitate platelet biogenesis or extend platelet lifespan. While not wishing to be bound by theory, it is believed that LLL can enhance the ATP synthesis by the mitochondria within platelets and/or platelet precursor cells, which, thereby, helps to enhance platelet biogenesis and extend the platelet lifespan. In some instances, LLL can facilitate in vitro and/or in vivo platelet biogenesis. In other instances, LLL can extend platelet lifespan in circulation. In still other instances, LLL can be employed to prolong the shelf-life of stored platelets.

A contact lens configured to decrease dark adaptation comprises one or more LEDs and directs light from the LED away from the fovea and toward the parafovea or perifoveal regions of the retain. In some embodiments, soft contact lens embedded with one or more arrays of microLEDs and electronics operating the LEDs is configured to be worn at night in order to inhibit dark adaptation and reduce oxygen consumption by the rods. The contact lens may be made of a single layer of a contact lens material or multiple layers sandwiching a flexible transparent plastic layer comprising the electronics and the LED arrays. The contact lens may be made of a hydrophilic hydrogel material that is biocompatible to the human cornea, or a silicone hydrogel material. The contact lens may be spherical and may provide refractive correction to the eye of the wearer.